Angiology

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems

Retrieved on: 
Lundi, avril 22, 2024
FDA, Physics, Food, Cleveland Clinic, Vascular disease, ICE, Doctor of Philosophy, Moyamoya disease, Patient, Physician, Circulatory system, Expanse, Angiology, Thrombectomy, Growth, Medical device

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.

Key Points: 
  • PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
  • The ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
  • The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies.
  • "The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time.

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems

Retrieved on: 
Lundi, avril 22, 2024
Physics, Food, Cleveland Clinic, Vascular disease, ICE, Doctor of Philosophy, Moyamoya disease, Patient, Physician, Circulatory system, Expanse, Angiology, Thrombectomy, Growth

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.

Key Points: 
  • PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
  • The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies.
  • Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE.
  • "The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time.

DEEPER OUS Trial Evaluating Reflow Medical’s Bare Temporary Spur Stent System Shows Positive Results at Six Months

Retrieved on: 
Mardi, juin 13, 2023
Health, Clinical Trials, Cardiology, Medical Devices, Medicine, Freedom, Senior, Calcification, Multimedia, Federal, Bare, MD, Patient, MALE, LINC, Research, Safety, POD, FESC, Angiology, Pharmaceutical industry, Telescopic sight, Medical device

Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of the Bare Temporary Spur Stent System.

Key Points: 
  • Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of the Bare Temporary Spur Stent System.
  • In 38 patients with a total of 40 lesions treated with the Bare Temporary Spur Stent System, results demonstrated:
    a trend toward improved six-month patency in subjects without vessel recoil.
  • Prof. Zeller discussed these and other results in his presentation, “DEEPER OUS trial - Vessel Recoil Sub-study: Initial Insights.”
    The Bare Temporary Spur Stent System is designed to deliver a temporary stent with integrated radial spikes to the peripheral vasculature via a sheathed delivery system, for stent-like results while leaving nothing behind.
  • “We’re looking forward to continuing to see great results from the study.”
    The Bare Temporary Spur Stent System is for investigational use only.

New Multidisciplinary Course Directors Join Lineup of HMP Global's 2022 Amputation Prevention Symposium

Retrieved on: 
Mardi, avril 5, 2022
Anatomy, Medical school, Memorial Sloan Kettering Cancer Center, Surgery, American Board of Commissioners for Foreign Missions, CEO, Course, Gaps, University of Texas Health Science Center Department of Radiology, Education, Evolution, PAD, LINC, Cornell University, Health, Advanced cardiac life support, Nursing, CME, Massachusetts General Hospital, Faculty, Amputation, Harvard Medical School, Thrombosis, Gender, Department, CLI, Diabetes, Mass, AT, EMT, CNE, Internal medicine, The Co Founder, Intermittent claudication, Patient, AMP, EMS, Thromboelastography, Hospital, Cancer, Teaching hospital, Assistant, VRTX, SAWC, Bypass surgery, LEAPP, Physician, News, Symposium, Breast cancer, Medical University of Graz, Medicine, Medical device, Medical imaging, Telescopic sight, Angiology, Psychotherapy, Radiology, DRS

MALVERN, Pa., April 5, 2022 /PRNewswire-PRWeb/ -- Four world-renowned faculty presenters are joining the Course Director lineup for HMP Global's 2022 Amputation Prevention Symposium (AMP), the only meeting dedicated to addressing the need for education and technologies for treating critical limb ischemia (CLI) in patients facing amputation.

Key Points: 
  • The four internationally recognized physicians will deliver presentations to guide healthcare professionals treating critical limb ischemia in patients facing amputation.
  • MALVERN, Pa., April 5, 2022 /PRNewswire-PRWeb/ -- Four world-renowned faculty presenters are joining the Course Director lineup for HMP Global's 2022 Amputation Prevention Symposium (AMP), the only meeting dedicated to addressing the need for education and technologies for treating critical limb ischemia (CLI) in patients facing amputation.
  • The event, now in its 12th year, will take place Aug. 17-20 in Chicago, and offers training and learning opportunities for participating clinicians.
  • "We have worked hard to build an agenda with more than 70 multidisciplinary experts, and the additions of Drs.

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Retrieved on: 
Mercredi, juillet 28, 2021
Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Vascular surgery, Interventional radiology, Thoracic aortic aneurysm, Aneurysm, Aortic aneurysm, Stent, Gustavo S. Oderich, Endovascular aneurysm repair

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Retrieved on: 
Mercredi, juillet 28, 2021
Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Vascular surgery, Interventional radiology, Thoracic aortic aneurysm, Aneurysm, Aortic aneurysm, Stent, Gustavo S. Oderich, Endovascular aneurysm repair

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

ForwardVue Pharma Appoints Bob Katz as Chief Executive Officer

Retrieved on: 
Mardi, juillet 27, 2021
Angiology, Angiogenesis, Macular degeneration, Medical specialties, Organ systems, Clinical medicine

BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Key Points: 
  • BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
  • Bob Katz is a seasoned life science executive bringing broad, multi-disciplinary expertise in early-stage technology development, clinical applications and successful fundraising.
  • Most recently, Katz was CEO and President of ContraMed where he directed the company from the pre-clinical stage to a successful Phase 3 Clinical Trial and exit.
  • Prior to ContraMed, Katz has held multiple C-level positions at venture-backed startups.

Aurion Biotech Announces IOTA Cell Therapy Trial

Retrieved on: 
Dimanche, juillet 25, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Optical, Hospitals, Surgery, Genetics, Clinical trials, Health sciences, Life sciences, Medical specialties, Angiology, Endothelium, Therapy, Corneal Endothelial Disease, Corneal Endothelial Cell Therapy, Aurion Biotech, CORNEAL ENDOTHELIAL DISEASE, CORNEAL ENDOTHELIAL CELL THERAPY, AURION BIOTECH

In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell therapy procedure first developed by Professor Shigeru Kinoshita and colleagues at Kyoto Prefecture University of Medicine (KPUM).

Key Points: 
  • In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell therapy procedure first developed by Professor Shigeru Kinoshita and colleagues at Kyoto Prefecture University of Medicine (KPUM).
  • The IOTA trial is the first corneal endothelial cell therapy procedure to be performed successfully outside of Japan, with Drs.
  • The IOTA trial was conducted as a proof of concept of previous studies of the cell therapy procedure developed by Professor Kinoshita and his KPUM colleagues.
  • Aurion Biotech intends to publish key findings in the future, in order to contribute to a greater medical and scientific understanding of corneal endothelial cell therapy.

Stimulating blood vessel formation with magnets

Retrieved on: 
Mercredi, juillet 21, 2021
Branches of biology, Biology, Angiology, Stem cells, Growth factors, Vascular endothelial growth factor, Biotechnology, Endothelium, Stromal cell, Mesenchymal stem cell, Cell therapy, Craniofacial regeneration

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

Philips receives FDA Breakthrough Device Designation for laser-assisted IVC filter removal device

Retrieved on: 
Mercredi, juillet 21, 2021
Medical specialties, Angiology, Inferior vena cava filter, Interventional radiology, Clinical medicine, Inferior vena cava, IVC, Deep vein thrombosis, Filtration, Filter, Electronic filter, Water filter

Limited options exist for embedded IVC filter removal, and independent studies indicate high success rates using a Philips excimer laser sheath

Key Points: 
  • Limited options exist for embedded IVC filter removal, and independent studies indicate high success rates using a Philips excimer laser sheath
    Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the FDA has granted Breakthrough Device Designation (BDD) for a laser-assisted inferior vena cava (IVC) filter removal device.
  • The proposed device is intended for ablating tissue to remove an IVC filter when previous methods of removal have failed.
  • Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion.
  • The failure rate for IVC filter removal is high and limited options for removal exist if the filter has become difficult to remove.